Category Archives: Genomics

Hopefully, Gwyneth Paltrow won’t get involved in this (boldface mine): Recently, Vitaliy Husar received results from a DNA screening that changed his life. It wasn’t a gene that suggested a high likelihood of cancer or a shocking revelation about his … Continue reading →

We’ll get to what CTX-M is in a bit, but first some biology background. Let’s talk about some game theory carbapenem antibiotics (also referred to as carbapenems): Before we get started, let’s do a quick biology review. A serious health … Continue reading →

While everyone hunts for the Holy Grail of human genomic sequencing (and other large genome critters), I’ve noted before there’s an obvious, if less sexy, market: …microbial genomes are cheap, fast, and you can provide epidemiological relevant information to clinical … Continue reading →

There’s a very interesting article that came out recently describing the first public report of carbapenem resistance in E. coli from the U.S. food supply. Maryn McKenna provides a good overview: Bacteria containing a gene that confers resistance to a … Continue reading →

One of the things the evul federal gummint is gearing up to every food borne bacterial disease isolate that is sent to either the CDC or public health labs in what is known as the GenomeTrakr Network (I’ve heard this … Continue reading →

I heard this talk almost a year ago*, so I’m glad this paper is finally out (I’ll translate into English below; boldface mine): The increasing prevalence of multidrug-resistant (MDR) bacteria is a serious global challenge. Here, we studied prospectively whether … Continue reading →

I’ve made this point about the role of funders before, but Fiona Nelson is absolutely right (boldface mine): Genomics is a data science. The human genome is vast – 3 billion base pairs. To make any significant findings from the … Continue reading →